Revenue: UK£552.0m (down 18% from FY 2024). Net income: UK£338.0m (up from UK£1.00m loss in FY 2024). Profit margin: 61% (up from net loss in FY 2024). EPS: UK£0.35 (up from UK£0.001 loss in FY 2024). We’ve discovered 3 warning signs about British Land. View them for free. LSE:BLND Earnings and Revenue Growth May 24th
Roper Technologies, Inc. Increasing full year guidance SARASOTA, Fla., April 28, 2025 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) reported financial results for the first quarter ended March 31, 2025. First quarter 2025 highlights Revenue increased 12% to $1.88 billion; acquisition contribution was +8% and organic revenue was +5% GAAP net earnings decreased 13%
Jelmyto Sales: $20.3 million in Q1 2025, 8% year-over-year growth. Revenue Growth: Driven by 12% underlying demand growth. R&D Expenses: $19.9 million in Q1 2025, up from $15.5 million in Q1 2024. SG&A Expenses: $35 million in Q1 2025, up from $27.3 million in Q1 2024. Net Loss: $43.8 million or $0.92 per share in
Total Revenue of $17.3 million Wealth Revenue growth of 41% over prior year Payments Revenue growth of 34% over prior year Solid Balance Sheet with Cash1, Marketable Securities & Investments of $38.8 million Mogo reports in Canadian dollars and in accordance with IFRS VANCOUVER, British Columbia, May 08, 2025–(BUSINESS WIRE)–Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) (“Mogo” or
Recent Business Highlights: Signed a Record Total Contract Value Deal: This multi-million dollar contract over a multi-year period speaks to our customer value proposition and our continued success moving upmarket. Unveiled B2 Cloud Storage Overdrive: New offering provides high performance throughput at great value, optimized for data-intensive workloads such as training AI models. Deepened Strategic
Revenue: $139 million in Q1 2025, representing 28% growth over Q1 2024. Crysvita Revenue: $103 million, with 25% growth over 2024; $41 million from North America, $55 million from Latin America and Turkey, $7 million from Europe. Dojolvi Revenue: $17 million, consistent with steady growth. Evkeeza Revenue: $11 million, with increasing demand following launches outside
Collaboration Revenue: $13.8 million in the first quarter of 2025, a 21% increase from the fourth quarter of 2024. R&D Expenses: $22.8 million in Q1 2025, a 68% decrease compared to the same period in 2024, and a nearly 40% decrease compared to Q4 2024. SG&A Expenses: $57.6 million in the first quarter of 2025.
Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash
First Quarter Consolidated Results Operating Revenues: Operating revenues were $745.8 million, up 9.7%. Organic operating revenue growth was 9.9%. The $65.9 million increase was the result of a $39.6 million increase in recurring subscription revenues and a $27.2 million increase in asset-based fees, partially offset by a $0.9 million decrease in non-recurring revenues. Run Rate
Construction Machinery Q4 Earnings: Astec (NASDAQ:ASTE) is the Best in the Biz The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Astec (NASDAQ:ASTE) and the rest of the construction machinery stocks fared in